Improving the Likelihood of Success in Trials and the Efficiency of Delivery of Mucolytics and Antibiotics

The use of models estimating the dosage delivered to a lung region to help design delivery systems for new drugs is well established (e.g. Finlay et al. (1997)). This approach, also called in silico testing, however has not yet received regulatory acceptance (Forbes et al. (2011)). A far less common application of lung deposition models is in the estimation of the concentration of the inhaled drug in the liquid layer that coats the human airways, also know as the airway surface liquid (ASL).